Loading...

DYAI DYADIC INTERNATIONAL INC Company Mergers 8-K Filing

DYDC

DY

DYADIC INTERNATIONAL INC

(DYAI)

2026 8-K

Collaboration Announcement

Quarterly Results

Delisting Notice

Annual Results Announcement

Stock Sale Agreement

Debt Agreement Update

Delisting Notice

Quarterly Results

Regained Compliance

Security Agreement Update

Quarterly Results

Equity Offerings

Market Expansion

Notice of Delisting

Notice of Delisting

Financial Statements

Debt-Equity Swaps

Financial Results

Funding Announcement

Gates Foundation Grant

Management Appointment

Convertible Note Amendment

Quarterly Results

Agreement with Proliant Bio...

Agreement with Proliant Bio...

Annual Meeting Voting Results

Earnings Reports

Financial Results and Leade...

Securities Purchase Agreement

Financial Results Announcement

Collaboration Agreement

Termination of Agreement

Agreement with INZYMES for ...

Earnings Reports

Annual Meeting of Shareholders

Earnings Reports

Licensing Agreement with Ru...

Accountant Change

Financial Results Announcement

Bylaws Amendment

Update on COVID-19 Vaccine ...

Resignation of Accountant

Clinical Trial Initiation

Other Special Situation

External Links:

On May 28, 2026, Dyadic International Inc. announced a collaboration with Scripps Research to develop a rapid-response hantavirus antibody and vaccine, leveraging their C1 platform for scalable biologic production.

AI Assistant

DYADIC INTERNATIONAL INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.